Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks

Abstract Introduction Patients with ankylosing spondylitis (AS) are burdened with symptoms impacting work productivity measured by presenteeism, absenteeism, overall work impairment, and activity impairment. Ixekizumab, a high-affinity monoclonal antibody selectively targeting interleukin-17A, has b...

Description complète

Détails bibliographiques

Auteurs principaux:	Helena Marzo-Ortega, Philip J. Mease, Proton Rahman, Victoria Navarro-Compán, Vibeke Strand, Maxime Dougados, Bernard Combe, James Cheng-Chung Wei, Xenofon Baraliakos, Theresa Hunter, David Sandoval, Xiaoqi Li, Baojin Zhu, Louis Bessette, Atul Deodhar
Format:	Artigo
Langue:	Inglês
Publié:	Adis, Springer Healthcare 2020-08-01
Collection:	Rheumatology and Therapy
Sujets:	Ankylosing spondylitis Axial spondyloarthritis Ixekizumab Radiographic axial spondyloarthritis Work productivity
Accès en ligne:	https://doi.org/10.1007/s40744-020-00225-4
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!